Multiple myeloma: Diagnosis and treatment

S Vincent Rajkumar, Robert A. Kyle

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Major advances have occurred in our understanding of the biology of multiple myeloma (MM) and in its treatment in the past decade. Mew diagnostic criteria have been developed, and an International Staging System has replaced the Durie-Salmon Staging System. It is now possible to classify MM as standard risk or high risk on the basis of specific independent prognostic factors. The role of single and double autologous stem cell transplantation has been clarified by randomized trials. Most importantly, thalidomide, bortezomib, and lenalidomide have emerged as new active agents and are being incorporated rapidly into the treatment of both newly diagnosed and relapsed MM. The current approach to the diagnosis, prognosis, and management of MM is reviewed.

Original languageEnglish (US)
Pages (from-to)1371-1382
Number of pages12
JournalMayo Clinic Proceedings
Volume80
Issue number10
StatePublished - 2005

Fingerprint

Multiple Myeloma
Thalidomide
Salmon
Stem Cell Transplantation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Multiple myeloma : Diagnosis and treatment. / Rajkumar, S Vincent; Kyle, Robert A.

In: Mayo Clinic Proceedings, Vol. 80, No. 10, 2005, p. 1371-1382.

Research output: Contribution to journalArticle

Rajkumar, SV & Kyle, RA 2005, 'Multiple myeloma: Diagnosis and treatment', Mayo Clinic Proceedings, vol. 80, no. 10, pp. 1371-1382.
Rajkumar, S Vincent ; Kyle, Robert A. / Multiple myeloma : Diagnosis and treatment. In: Mayo Clinic Proceedings. 2005 ; Vol. 80, No. 10. pp. 1371-1382.
@article{d5f5c9e790e645e9a2f4ec7dc67b675f,
title = "Multiple myeloma: Diagnosis and treatment",
abstract = "Major advances have occurred in our understanding of the biology of multiple myeloma (MM) and in its treatment in the past decade. Mew diagnostic criteria have been developed, and an International Staging System has replaced the Durie-Salmon Staging System. It is now possible to classify MM as standard risk or high risk on the basis of specific independent prognostic factors. The role of single and double autologous stem cell transplantation has been clarified by randomized trials. Most importantly, thalidomide, bortezomib, and lenalidomide have emerged as new active agents and are being incorporated rapidly into the treatment of both newly diagnosed and relapsed MM. The current approach to the diagnosis, prognosis, and management of MM is reviewed.",
author = "Rajkumar, {S Vincent} and Kyle, {Robert A.}",
year = "2005",
language = "English (US)",
volume = "80",
pages = "1371--1382",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Multiple myeloma

T2 - Diagnosis and treatment

AU - Rajkumar, S Vincent

AU - Kyle, Robert A.

PY - 2005

Y1 - 2005

N2 - Major advances have occurred in our understanding of the biology of multiple myeloma (MM) and in its treatment in the past decade. Mew diagnostic criteria have been developed, and an International Staging System has replaced the Durie-Salmon Staging System. It is now possible to classify MM as standard risk or high risk on the basis of specific independent prognostic factors. The role of single and double autologous stem cell transplantation has been clarified by randomized trials. Most importantly, thalidomide, bortezomib, and lenalidomide have emerged as new active agents and are being incorporated rapidly into the treatment of both newly diagnosed and relapsed MM. The current approach to the diagnosis, prognosis, and management of MM is reviewed.

AB - Major advances have occurred in our understanding of the biology of multiple myeloma (MM) and in its treatment in the past decade. Mew diagnostic criteria have been developed, and an International Staging System has replaced the Durie-Salmon Staging System. It is now possible to classify MM as standard risk or high risk on the basis of specific independent prognostic factors. The role of single and double autologous stem cell transplantation has been clarified by randomized trials. Most importantly, thalidomide, bortezomib, and lenalidomide have emerged as new active agents and are being incorporated rapidly into the treatment of both newly diagnosed and relapsed MM. The current approach to the diagnosis, prognosis, and management of MM is reviewed.

UR - http://www.scopus.com/inward/record.url?scp=25844477041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844477041&partnerID=8YFLogxK

M3 - Article

C2 - 16212152

AN - SCOPUS:25844477041

VL - 80

SP - 1371

EP - 1382

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -